China Ramps Up Charm Offensive to Counter Trump's Trade Mayhem
Hi, this is Colum Murphy, writing from the coastal town of Boao, where China is stepping up its charm offensive and pitching itself as a pillar of global stability in an increasingly volatile world — courtesy of President Donald Trump.
While the US hit trading partners with auto tariffs and vowed broader measures next week, the Boao Forum — often called China's Davos — gathered government officials and corporate heavyweights like Xiaomi's Lei Jun, AstraZeneca's Pascal Soriot and Fortescue's Andrew Forrest to push for stronger cooperation across Asia.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
5 top FTSE 100 stocks offering plenty of global growth for an ISA
The FTSE 100 is made up of the largest companies listed in London. But this doesn't mean that most stocks are UK-focused, far from it. In fact, it's quite straightforward to build a Stocks and Shares ISA portfolio of FTSE 100 shares that offer truly global exposure. Here are five that would certainly do the job. Let's start with the largest stock by market cap in the Footsie today: AstraZeneca (LSE: AZN). This healthcare giant has truly global operations, spanning the areas of oncology, respiratory and immunology, rare diseases, and more. This year, the firm is expected to rake in $57.5bn in revenue, with a net profit of about $14bn. And it generates this from nearly everywhere, including China and Japan. Region % of total revenue (2024) US 40% Europe 16% China 12% UK 9% Japan 6% Rest of world 17% As we can see, investors in AstraZeneca are getting diversified exposure to the whole of the developed world. The reason the US is such a sizeable part is because it has the largest healthcare system of them all. The stock has fallen 17.5% since the end of August, putting it on a forward price-to-earnings (P/E) ratio of 15.5. For a profitable firm of this calibre, which also offers a 2.3% dividend yield, I think that's very attractive. Turning to another FTSE 100 giant now, we have HSBC (LSE: HSBA). The bank is increasingly focused on Asia these days, as that's where most of the world's growth is expected to come from in future. Indeed, according to the Asian Development Bank, Asia's middle class is set to swell to roughly 3bn people by 2050. With HSBC increasingly focused on wealth management in the region, the long-term growth story looks very promising. This year, the bank is expected to earn around $23bn on revenue of almost $67bn. The stock is offering an attractive 5.8% dividend yield. The third stock is Airtel Africa. As the name implies, the firm's operations extend across Africa. Specifically, Airtel is a provider of telecommunications and mobile money services to 166m people in 14 countries in sub-Saharan Africa. The share price has been on a tear, surging 55% this year alone. However, it still looks decent value to me, trading at 12.5 times next year's forecast earnings. There's also a well-supported 2.8% dividend yield. Finally, for even more global portfolio exposure, investors could consider Coca Cola HBC and Coca-Cola Europacific Partners. These are both bottling partners for the US beverage giant, selling brands like Coca-Cola, Fanta, Sprite, and Monster. The former's markets include Western Europe and the Asia-Pacific region, including Australia, New Zealand, and the Philippines. The other's portfolio is more weighted toward emerging and developing markets, including Poland, Romania, Nigeria, and Egypt. Naturally, none of these five stocks are totally risk-free. The Coca-Cola bottlers could suffer during a severe global economic downturn, as this would put pressure on consumer spending. Meanwhile, HSBC and AstraZeneca may fall foul of regulatory changes in China, especially if trade tensions with the US worsen at some point. Finally, most of Airtel Africa's revenue is collected in local African currencies, but it's reported in US dollars, exposing the company to currency risk. Nevertheless, adding these stocks to an ISA would make it truly global, with vast exposure to Europe, America, Africa, and Asia. The post 5 top FTSE 100 stocks offering plenty of global growth for an ISA appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool HSBC Holdings is an advertising partner of Motley Fool Money. Ben McPoland has positions in AstraZeneca Plc, Coca-Cola Hbc Ag, and HSBC Holdings. The Motley Fool UK has recommended Airtel Africa Plc, AstraZeneca Plc, and HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 days ago
- Associated Press
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. ('Tempus' or the 'Company') (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. If you purchased or otherwise acquired Tempus shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 [email protected]
Yahoo
2 days ago
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
